Brooks, Moore & Associates, Inc. Mei Pharma, Inc. Transaction History

Brooks, Moore & Associates, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.21 - $0.35 $4,973 - $8,289	23,685 New	23,685 $5,000
Q4 2020 Feb 08, 2021	SELL	$2.6 - $3.32 $28,301 - $36,138	-10,885 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$2.46 - $4.27 $26,777 - $46,478	10,885 New	10,885 $34,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Brooks, Moore & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Brooks, Moore & Associates, Inc. with notifications on news.